Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS
Primary Purpose
Anovulatory Infertility Related to Polycystic Ovary Syndrome
Status
Unknown status
Phase
Phase 4
Locations
Italy
Study Type
Interventional
Intervention
Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
Sponsored by
About this trial
This is an interventional treatment trial for Anovulatory Infertility Related to Polycystic Ovary Syndrome focused on measuring Anovulation, Clomiphene citrate, Infertility, Metformin, PCOS, RCT, Treatment
Eligibility Criteria
Inclusion Criteria:
- Polycystic ovary syndrome (using ESHRE/ARSM 2004 criteria)
Exclusion Criteria:
- Age <18 or >35 years
- Severe obesity (BMI >35)
- Neoplastic, metabolic, hepatic, and cardiovascular disorders or other concurrent medical illnesses
- Hypothyroidism, hyperprolactinemia, Cushing's syndrome, and non-classical congenital adrenal hyperplasia
- Current or previous (within the last six months) use of oral contraceptives, glucocorticoids, antiandrogens, antidiabetic and anti-obesity drugs or other hormonal drugs
- Previous use of ovulation induction agents
- Intention to start a diet or a specific program of physical activity
- No uterine bleeding after progesterone challenge test
- Organic pelvic diseases
- Previous pelvic surgery
- Suspected peritoneal factor infertility
- Tubal or male factor infertility or sub-fertility
Sites / Locations
- "Pugliese" HospitalRecruiting
- "Pugliese" HospitalRecruiting
- Pugliese-Ciaccio HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
Strategy A
Strategy B
Strategy C
Arm Description
clomiphene followed by clomiphene plus metformin followed by gonadotropins
metformin followed by metformin plus clomiphene followed by gonadotropins
metformin plus clomiphene followed by gonadotropins
Outcomes
Primary Outcome Measures
Multiple pregnancy rate
Secondary Outcome Measures
Ovulation rate
Pregnancy rate
Abortion rate
Live-birth rate
Adverse-events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00461643
Brief Title
Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS
Official Title
Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2013
Overall Recruitment Status
Unknown status
Study Start Date
January 2007 (undefined)
Primary Completion Date
December 2015 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Magna Graecia
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Anovulatory infertility is a common feature of the polycystic ovary syndrome (PCOS). Even if several first-step treatments have been proposed for anovulatory infertile PCOS patients, very few data are available in literature regarding the best integrated strategy. In fact, a single compound could be effective as first-step approach but not or less useful when integrated in a more complex strategy.
The goal of the current protocol will be to compare three different strategies for treating anovulatory infertility in PCOS patients having as primary end-point the multiple pregnancy rate.
Detailed Description
All patients eligible will undergo baseline assessment consisting of antropometric, hormonal, and ultrasonographic assessments. Successively, patients enrolled will be allocated in three different strategies (strategy A, B, and C).
A total of 184 infertile PCOS patients per arm will be enrolled and treated with three different integrated strategies: clomiphene followed by clomiphene plus metformin followed by gonadotropins (strategy A); metformin followed by metformin plus clomiphene followed by gonadotropins(strategy B); and metformin plus clomiphene followed by gonadotropins(strategy C).
In all patients, the same regimen will be used to administered clomiphene, metformin, and gonadotropins.Both clomiphene and metformin will be administered at incremental doses in each case.Gonadotropins will be administrated to obtain a controlled ovarian stimulation using highly purified urinary FSH in a low-dose step-up protocol.
During the study, the clinical and reproductive outcomes, and adverse experiences will be evaluated in each woman.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anovulatory Infertility Related to Polycystic Ovary Syndrome
Keywords
Anovulation, Clomiphene citrate, Infertility, Metformin, PCOS, RCT, Treatment
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
552 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Strategy A
Arm Type
Active Comparator
Arm Description
clomiphene followed by clomiphene plus metformin followed by gonadotropins
Arm Title
Strategy B
Arm Type
Active Comparator
Arm Description
metformin followed by metformin plus clomiphene followed by gonadotropins
Arm Title
Strategy C
Arm Type
Active Comparator
Arm Description
metformin plus clomiphene followed by gonadotropins
Intervention Type
Drug
Intervention Name(s)
Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
Primary Outcome Measure Information:
Title
Multiple pregnancy rate
Time Frame
9 months
Secondary Outcome Measure Information:
Title
Ovulation rate
Time Frame
15 months
Title
Pregnancy rate
Time Frame
15 months
Title
Abortion rate
Time Frame
15 months
Title
Live-birth rate
Time Frame
24 months
Title
Adverse-events
Time Frame
15
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Polycystic ovary syndrome (using ESHRE/ARSM 2004 criteria)
Exclusion Criteria:
Age <18 or >35 years
Severe obesity (BMI >35)
Neoplastic, metabolic, hepatic, and cardiovascular disorders or other concurrent medical illnesses
Hypothyroidism, hyperprolactinemia, Cushing's syndrome, and non-classical congenital adrenal hyperplasia
Current or previous (within the last six months) use of oral contraceptives, glucocorticoids, antiandrogens, antidiabetic and anti-obesity drugs or other hormonal drugs
Previous use of ovulation induction agents
Intention to start a diet or a specific program of physical activity
No uterine bleeding after progesterone challenge test
Organic pelvic diseases
Previous pelvic surgery
Suspected peritoneal factor infertility
Tubal or male factor infertility or sub-fertility
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stefano Palomba, MD
Phone
+39-0961.883234
Email
stefanopalomba@tin.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefano Palomba, MD
Organizational Affiliation
Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro
Official's Role
Principal Investigator
Facility Information:
Facility Name
"Pugliese" Hospital
City
Catanzaro
ZIP/Postal Code
88100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ingrid Tomaino, MD
Phone
+39 0961 883234
Email
angela.falbo@libero.it
First Name & Middle Initial & Last Name & Degree
Stefano Palomba, MD
Facility Name
"Pugliese" Hospital
City
Catanzaro
ZIP/Postal Code
88100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ingrid Tomaino, MD
Phone
+39 0961 883234
Email
zullo@unicz.it
First Name & Middle Initial & Last Name & Degree
Stefano Palomba, MD
First Name & Middle Initial & Last Name & Degree
Francesco Orio, MD
First Name & Middle Initial & Last Name & Degree
Achille Tolino, MD
First Name & Middle Initial & Last Name & Degree
Pasquale Mastrantonio, MD
First Name & Middle Initial & Last Name & Degree
Brian Dale, MD
First Name & Middle Initial & Last Name & Degree
Ettore Cittadini, MD
First Name & Middle Initial & Last Name & Degree
Andrea Riccardo Genazzani, MD
Facility Name
Pugliese-Ciaccio Hospital
City
Catanzaro
ZIP/Postal Code
88100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
MD
12. IPD Sharing Statement
Citations:
PubMed Identifier
15840746
Citation
Palomba S, Orio F Jr, Falbo A, Manguso F, Russo T, Cascella T, Tolino A, Carmina E, Colao A, Zullo F. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Jul;90(7):4068-74. doi: 10.1210/jc.2005-0110. Epub 2005 Apr 19.
Results Reference
background
PubMed Identifier
16769748
Citation
Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 2006 Jun 24;332(7556):1485. doi: 10.1136/bmj.38867.631551.55. Epub 2006 Jun 12.
Results Reference
background
PubMed Identifier
17287476
Citation
Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007 Feb 8;356(6):551-66. doi: 10.1056/NEJMoa063971.
Results Reference
background
Learn more about this trial
Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS
We'll reach out to this number within 24 hrs